drugset / Trial / NCT01777477
Adjuvant Effect of Chloroquine on Gemcitabine
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety by defining the maximum tolerated dose (MTD) of Choloroquine when combined with Gemcitabine, and to evaluate preliminary efficacy of combined systemic Gemcitabine and Chloroquine. In addition, the influence of the treatment on the anti-cancer immunity and the value of GOLPH2 as serum marker for pancreatic cancer will be assessed within a translational objective. * Trial with medicinal product
Timeline
- Start
- 2012-07
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chloroquine | Small molecule | 100 mg | Oral |
| Subject | Chloroquine | Small molecule | 200 mg | Oral |
| Subject | Chloroquine | Small molecule | 300 mg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |